Suggested Remit: To appraise the clinical and cost effectiveness of adjunctive cenobamate within its marketing authorisation for treating focal onset seizures in epilepsy.
 
Status In progress
Process STA 2018
ID number 1553

Provisional Schedule

Committee meeting: 2 06 October 2021
Expected publication 15 December 2021

Project Team

Project lead Jo Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Consultees

Companies sponsors Arvelle Therapeutics (cenobamate)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Epilepsy Action
  Young Epilepsy
Professional groups Royal College of Physicians
  UK Clinical Pharmacy Association

Commentators

Associated public health groups None
Comparator companies Eisai (eslicarbazepine acetate, perampanel)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
31 August 2021 - 21 September 2021 Appraisal consultation: 1
05 August 2021 Committee meeting: 1
21 January 2021 Please note that due to operational issues the timelines for this appraisal have now been updated. Therefore, the appraisal committee meeting for this topic has been rescheduled. The technical engagement period for this appraisal is now scheduled to start in mid-April 2021. The new committee date will be Wednesday 4 August 2021.
29 September 2020 Invitation to participate
29 September 2020 In progress. In progress
27 July 2020 (10:00) Scoping workshop
10 June 2020 - 08 July 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance